Featured Research

from universities, journals, and other organizations

Young children respond well to recommended swine flu vaccine, study suggests

Date:
June 1, 2010
Source:
BMJ-British Medical Journal
Summary:
The first head to head study of the two H1N1 vaccines used in the UK during the recent pandemic finds that the adjuvanted split virus vaccine induced higher immune response rates in young children, but was associated with more reactions than the whole virus vaccine.

The first head to head study of the two H1N1 vaccines used in the UK during the recent pandemic finds that the adjuvanted split virus vaccine induced higher immune response rates in young children, but was associated with more reactions than the whole virus vaccine.

These data provide important information to guide immunisation policy in an influenza pandemic, say the researchers.

During the 2009-10 influenza A (H1N1) pandemic, children experienced pandemic A (H1N1) infections at four times the rate of adults and were more commonly admitted to hospital, making them a priority group for vaccination.

The Department of Health purchased two H1N1 vaccines for the national immunisation programme, an adjuvanted split virion vaccine derived from egg culture and a non-adjuvanted whole virion vaccine derived from cell culture.

A team of UK researchers therefore set out to evaluate the safety, reactogenicity (tendency to cause reactions), and immunogenicity (ability to induce an antibody response) of the two vaccines in children aged 6 months to 12 years, to inform the scientific community, policy makers and parents.

Over 900 children participated in the study, which took place at five UK centres between 26 September and 11 December 2009, during the second wave of the pandemic in the UK. Children were grouped by age and were randomised to receive either the split vaccine or the whole virus vaccine in two doses, 21 days apart.

Details of reactions, such as fever, tenderness, swelling and redness of the skin, were collected for one week after vaccination. Blood samples were taken before vaccination and after the second dose to measure rises in antibody levels (a process known as seroconversion).

Both vaccines were well tolerated. The split virus vaccine was more immunogenic and achieved higher seroconversion rates than the whole virus vaccine, especially in children aged less than 3 years. The split virus vaccine was also associated with more reactions compared with the whole virus vaccine, although these reactions were generally in keeping with the product data produced by the manufacturer. Significantly fewer reactions, including fever, were observed after a first dose of adjuvanted vaccine than a second, especially in younger children.

The authors conclude: "In this first direct comparison of an AS03B adjuvanted split virion versus whole virion non-adjuvanted H1N1 vaccine, the adjuvanted vaccine, while more reactogenic, was more immunogenic and, importantly, achieved high seroconversion rates in children aged less than 3 years. This indicates the potential for improved immunogenicity of influenza vaccines in this age group."


Story Source:

The above story is based on materials provided by BMJ-British Medical Journal. Note: Materials may be edited for content and length.


Journal Reference:

  1. Claire S Waddington et al. Safety and immunogenicity of AS03B adjuvanted split virion versus non-adjuvanted whole virion H1N1 influenza vaccine in UK children aged 6 months-12 years: open label, randomised, parallel group, multicentre study. BMJ, 2010;340:c2649 DOI: 10.1136/bmj.c2649

Cite This Page:

BMJ-British Medical Journal. "Young children respond well to recommended swine flu vaccine, study suggests." ScienceDaily. ScienceDaily, 1 June 2010. <www.sciencedaily.com/releases/2010/05/100527204229.htm>.
BMJ-British Medical Journal. (2010, June 1). Young children respond well to recommended swine flu vaccine, study suggests. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/2010/05/100527204229.htm
BMJ-British Medical Journal. "Young children respond well to recommended swine flu vaccine, study suggests." ScienceDaily. www.sciencedaily.com/releases/2010/05/100527204229.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins